Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726424 | 0.81 | MAPT (0.41) | TSHRLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL5726367 | 0.77 | ABCB1 (0.50) | TSHRMAPTALDH1A1KMT2ACYP2C19 | |
| SCHEMBL3957456 | 0.70 | — | — | |
| SCHEMBL5726650 | 0.70 | TP53 (0.48) | TSHRLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL5726333 | 0.70 | MAPT (0.41) | TSHRMAPTALDH1A1KMT2ACYP1A2 | |
| SCHEMBL5726244 | 0.69 | PIK3CD (0.36) | ALDH1A1 | |
| SCHEMBL5727573 | 0.68 | PIK3CD (0.43) | TSHRLMNACYP2C9 | |
| SCHEMBL5727576 | 0.68 | PIK3CD (0.43) | TSHRLMNACYP2C9 | |
| SCHEMBL5726530 | 0.67 | PIK3CD (0.37) | TSHRLMNAMAPTALDH1A1KMT2A | |
| SCHEMBL5727637 | 0.66 | ALDH1A1 (0.40) | TSHRMAPTALDH1A1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138404-B2 | 4-aminopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | claimed |
| EP-1395568-B1 | 4-AMINOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-11-02 | — | — | EP | claimed |
| EP-1395568-A1 | 4-AMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-10 | — | — | EP | claimed |
| US-20030022907-A1 | 4-aminopyrimidine derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-30 | — | — | US | claimed |
| WO-2002094795-A1 | 4-AMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | claimed |
| US-7138404-B2 | 4-aminopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1395568-B1 | 4-AMINOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-11-02 | — | — | EP | disclosed |
| EP-1395568-A1 | 4-AMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-20030022907-A1 | 4-aminopyrimidine derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2002094795-A1 | 4-AMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022907-A1 | 4-aminopyrimidine derivatives | GRM5, GRIK5, GRM1 | LRRK2 1536/4885PKM 1461/4885TSHR 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.